share_log

Leerink Partners Upgrades Blueprint Medicines to Market Perform, Raises Price Target to $97

Leerink Partners Upgrades Blueprint Medicines to Market Perform, Raises Price Target to $97

Leerink Partners将蓝图药物升级至市场表现,将目标股价上调至97美元
Benzinga ·  05/06 13:47

Leerink Partners analyst Andrew Berens upgrades Blueprint Medicines (NASDAQ:BPMC) from Underperform to Market Perform and raises the price target from $50 to $97.

Leerink Partners分析师安德鲁·贝伦斯将Blueprint Medicines(纳斯达克股票代码:BPMC)从表现不佳上调至市场表现,并将目标股价从50美元上调至97美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发